Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors), PIM3 inhibitors(Serine/threonine-protein kinase pim-3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Myeloblastic Leukemia | Phase 1 | CN | 04 Nov 2022 | |
Refractory acute myeloid leukemia | Phase 1 | CN | 04 Nov 2022 | |
Non-Hodgkin Lymphoma | Phase 1 | CN | 27 Oct 2022 | |
Relapsing acute myeloid leukemia | Phase 1 | CN | 27 Oct 2022 | |
Solid tumor | Phase 1 | CN | 30 Jan 2022 | |
Acute Myeloid Leukemia | Preclinical | AU | 29 Jun 2021 | |
B-Cell Lymphoma | Preclinical | AU | 29 Jun 2021 | |
Chronic Lymphocytic Leukemia | Preclinical | AU | 29 Jun 2021 | |
Small Lymphocytic Lymphoma | Preclinical | AU | 29 Jun 2021 | |
B-Cell Lymphoma | Discovery | AU | 29 Jun 2021 |